Grants and Contributions:
Title:
ARP - Feasibility: Development of Innovative Formulations of Maresin Analogs as Potential Treatment for Systemic Lupus Erythematosus (SLE).
Agreement Number:
1031076
Agreement Value:
$75,000.00
Agreement Date:
Jun 2, 2025 - Feb 20, 2026
Description:
With this project, the Firm propose to develop innovative formulations of a maresin compound.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1W 5C4
Reference Number:
172-2025-2026-Q1-1031076
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
787470707
Recipient Type:
For-profit organization
Recipient's Operating Name:
SPM Thérapeutique
Recipient's Legal Name:
SPM Therapeutics Inc.
Federal Riding Name:
Louis-Hébert
Federal Riding Number:
24044
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410